Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges

Shalini Arunogiri; Nicholas Lintzeris

doi:10.1016/j.jsat.2020.108221

Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges

Shalini Arunogiri
, Nicholas Lintzeris

Department of Psychiatry (STM)

Research output: Contribution to journal › Article › Research › peer-review

20 Citations (Scopus)

Abstract

The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.

Original language	English
Article number	108221
Number of pages	3
Journal	Journal of Substance Abuse Treatment
Volume	124
DOIs	https://doi.org/10.1016/j.jsat.2020.108221
Publication status	Published - 1 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Buprenorphine
Opioid
Opioid use disorder

Access to Document

10.1016/j.jsat.2020.108221

Cite this

@article{2c3c19c420434a9e8a7aaa09b53ba76d,

title = "Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges",

abstract = "The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.",

keywords = "Buprenorphine, Opioid, Opioid use disorder",

author = "Shalini Arunogiri and Nicholas Lintzeris",

year = "2021",

month = may,

day = "1",

doi = "10.1016/j.jsat.2020.108221",

language = "English",

volume = "124",

journal = "Journal of Substance Abuse Treatment",

issn = "0740-5472",

publisher = "Elsevier",

}

TY - JOUR

T1 - Depot buprenorphine during COVID-19 in Australia

T2 - Opportunities and challenges

AU - Arunogiri, Shalini

AU - Lintzeris, Nicholas

PY - 2021/5/1

Y1 - 2021/5/1

N2 - The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.

AB - The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.

KW - Buprenorphine

KW - Opioid

KW - Opioid use disorder

UR - https://www.scopus.com/pages/publications/85097735415

U2 - 10.1016/j.jsat.2020.108221

DO - 10.1016/j.jsat.2020.108221

M3 - Article

C2 - 33303254

AN - SCOPUS:85097735415

SN - 0740-5472

VL - 124

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

M1 - 108221

ER -

Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this